Recent recommendations are in favor of a treat-to-target approach in JIA in general [36] and SJIA in particular [37], with very ambitious targets such as achieving control of fever and marked reduction of CRP level within one week, complete remission off steroids after some months; this has also stimulated a very active therapeutic approach of patients suspected of SJIA at an early phase of the disease, with often a very early introduction of the anti-IL-1 receptor antagonist anakinra. The gene discussed is CRP; the disease is juvenile idiopathic arthritis.